Literature DB >> 31179657

Intravitreal Dexamethasone Implantation in Intravitreal Bevacizumab Treatment-resistant Pseudophakic Cystoid Macular Edema.

Ayse Gul Kocak Altintas1, Cagri Ilhan2.   

Abstract

PURPOSE: To evaluate the changes in visual acuity (VA) and central macular thickness (CMT) after intravitreal dexamethasone (IVD) implantation in intravitreal bevacizumab (IVB) treatment-resistant cases with pseudophakic cystoid macular edema (PCME).
METHODS: This study included 10 PCME cases who underwent uneventful phacoemulsification and intraocular lens implantation with similar methods and six PCME cases referred to our hospital for treatment of low VA after cataract surgery. Due to the persistence of PCME, both topical steroid and anti-inflammatory medication were administered first, followed by IVB injection. IVD implantation was performed for all IVB treatment-resistant cases. VA and CMT values were compared before and at three months after the first IVD implantation.
RESULTS: The mean VA values before and at 3 months after the first IVD implantation were 0.69 ± 0.19 logarithm of the minimum angle of resolution (logMAR) (1.50 to 0.10 logMAR) and 0.26 ± 0.07 logMAR (1.00 to 0.00 logMAR), respectively (p < 0.001). The mean CMT was 476.13 ± 135.13 mm (314 to 750 mm) and 294.06 ± 15.26 mm (222 to 480 mm), respectively (p < 0.001). The mean number of implanted IVD was 1.44 ± 0.89 (1 to 4) and the mean follow-up time was 7.4 ± 4.6 months (6 to 24 months). After IVD implantation therapy, the mean VA and CMT values were 0.19 ± 0.05 logMAR (0.70 to 0.00 logMAR) and 268.38 ± 31.35 mm (217 to 351 mm), respectively.
CONCLUSIONS: To the best of our knowledge, this is the first report to show the efficacy of IVD implantation even after repeated IVB injections in treatment-resistant PCME. IVD implantation is both a safe and effective method for decreasing PCME after both uneventful and complicated cataract surgery.
© 2019 The Korean Ophthalmological Society.

Entities:  

Keywords:  Bevacizumab; Dexamethasone; Macular edema; Pseudophakic cystoid macular edema

Mesh:

Substances:

Year:  2019        PMID: 31179657      PMCID: PMC6557797          DOI: 10.3341/kjo.2018.0106

Source DB:  PubMed          Journal:  Korean J Ophthalmol        ISSN: 1011-8942


  27 in total

1.  Macular alterations after small-incision cataract surgery.

Authors:  Conceição L Lobo; Pedro M Faria; Mário A Soares; Rui C Bernardes; José G Cunha-Vaz
Journal:  J Cataract Refract Surg       Date:  2004-04       Impact factor: 3.351

Review 2.  Pseudophakic cystoid macular edema.

Authors:  Nicole R Benitah; Jorge G Arroyo
Journal:  Int Ophthalmol Clin       Date:  2010

3.  Chronic macular edema medical treatment in Irvine-Gass syndrome: case report.

Authors:  Alessandro Randazzo; Paolo Vinciguerra
Journal:  Eur J Ophthalmol       Date:  2010 Mar-Apr       Impact factor: 2.597

4.  Intravitreal bevacizumab (Avastin) for refractory pseudophakic cystoid macular edema.

Authors:  John O Mason; Michael A Albert; Rachel Vail
Journal:  Retina       Date:  2006-03       Impact factor: 4.256

5.  Cystoid macular edema after phacoemulsification: relationship to blood-aqueous barrier damage and visual acuity.

Authors:  P G Ursell; D J Spalton; S M Whitcup; R B Nussenblatt
Journal:  J Cataract Refract Surg       Date:  1999-11       Impact factor: 3.351

6.  Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate.

Authors:  Michael J Tolentino; D Scott McLeod; Makoto Taomoto; Tsuyoshi Otsuji; Anthony P Adamis; Gerard A Lutty
Journal:  Am J Ophthalmol       Date:  2002-03       Impact factor: 5.258

7.  Efficacy of intravitreal bevacizumab in treating postoperative pseudophakic cystoid macular edema.

Authors:  Martin S Spitzer; Focke Ziemssen; Efdal Yoeruek; Katrin Petermeier; Sabine Aisenbrey; Peter Szurman
Journal:  J Cataract Refract Surg       Date:  2008-01       Impact factor: 3.351

8.  Successful treatment of pseudophakic cystoid macular edema with intravitreal bevacizumab.

Authors:  Antonio Barone; Francesco Prascina; Vincenzo Russo; Cristiana Iaculli; Vito Primavera; Giuseppe Querques; Andrea Stella; Nicola Delle Noci
Journal:  J Cataract Refract Surg       Date:  2008-07       Impact factor: 3.351

9.  Clinical pseudophakic cystoid macular edema. Risk factors for development and duration after treatment.

Authors:  Bonnie A Henderson; Jae Yong Kim; Christine S Ament; Zandra K Ferrufino-Ponce; Anna Grabowska; Sandra L Cremers
Journal:  J Cataract Refract Surg       Date:  2007-09       Impact factor: 3.351

10.  Intravitreal bevacizumab for refractory pseudophakic cystoid macular edema: the Pan-American Collaborative Retina Study Group results.

Authors:  J Fernando Arevalo; Mauricio Maia; Rafael A Garcia-Amaris; Jose A Roca; Juan G Sanchez; Maria H Berrocal; Lihteh Wu
Journal:  Ophthalmology       Date:  2009-07-09       Impact factor: 12.079

View more
  1 in total

1.  Epigenetic alterations associated with dexamethasone sodium phosphate through DNMT and TET in RPE cells.

Authors:  Wenjie Liu; Sruthi Priya Mohan; Nareshkumar Ragavachetty Nagaraj; Shyam Sundar Jaganathan; Yi Wen; Sharada Ramasubramanyan; Joseph Irudayaraj
Journal:  Mol Vis       Date:  2021-11-20       Impact factor: 2.367

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.